Rational therapeutic intervention in cancer: kinases as drug targets.
about
Tyrosine kinase - Role and significance in Cancer.Role of SHP-2 tyrosine phosphatase in the DNA damage-induced cell death response.A tumor-specific kinase activity regulates the viral death protein Apoptin.Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line.Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expressionSequence survey of receptor tyrosine kinases reveals mutations in glioblastomasHyperparathyroid genes: sequences reveal answers and questions.Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Death-associated protein kinase as a potential therapeutic target.Cloretazine for the treatment of acute myeloid leukemia.Human iPS Cell-Derived Neurons Uncover the Impact of Increased Ras Signaling in Costello SyndromeCAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer.Targeted therapies in the management of metastatic bladder cancerStem cell death and survival in heart regeneration and repair.Kinase dysfunction and kinase inhibitors.The antiproliferative effect of indomethacin-loaded lipid-core nanocapsules in glioma cells is mediated by cell cycle regulation, differentiation, and the inhibition of survival pathwaysAnti-leukemic effect of 2-pyrone derivatives via MAPK and PI3 kinase pathways.PTMScan direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS.Daunorubicin induces cell death via activation of apoptotic signalling pathway and inactivation of survival pathway in muscle-derived stem cells.A novel cyano derivative of 11-keto-β-boswellic acid causes apoptotic death by disrupting PI3K/AKT/Hsp-90 cascade, mitochondrial integrity, and other cell survival signaling events in HL-60 cells.Mutational analysis of the SH2-kinase linker region of Bruton's tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families.Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity.Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors.Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.Identification of molecular subtypes of glioblastoma by gene expression profiling.Targeted Therapy for Medullary Thyroid Cancer: A Review.Development of SH2 probes and pull-down assays to detect pathogen-induced, site-specific tyrosine phosphorylation of the TLR adaptor SCIMP.
P2860
Q24791430-087ABE03-ACD9-4E6A-B3E7-813DC229E10AQ30164884-68A3F4D6-77B7-4E37-A545-A89B068057DBQ31115267-D39BE59B-450A-4551-BCC3-E320BDF7D57BQ33303792-4D6F1053-455E-445C-A40F-64EF7F090BC4Q33978041-25AB835E-CACD-4055-8DEB-5025099D9886Q34063705-80F6953F-FED1-4D56-B9D5-95B283FE8935Q34628063-5FD7EE8D-057C-4AAC-981A-7A73C593C3BEQ34659415-FC16C861-427D-4733-AEF7-AACDAAF47556Q34837310-E08D2BDD-B0D3-4983-879C-72CBB168ABD7Q36407434-30FECFEE-19DE-4434-A61A-2F25A0B5DAE3Q36431974-E0557E59-7EB9-4F14-8FB2-3E3ABCA6F588Q37121911-301A6FED-F801-46DC-B1FB-6CAF3061D3C1Q37290448-BBC1DF43-D93F-4511-833B-A71302F7191CQ37545373-D99B261B-509D-49B3-A687-1EC130C845B0Q38075152-AB79FEEB-4DD3-41D3-A065-06ECF4148B54Q39188696-C135F7D7-2A56-4C30-A2C3-FD2A009F4974Q39360283-5D899FC8-0B58-4F4D-A676-E1FC7A298093Q39398876-A3EAA512-0461-44CF-914B-88E424ACFEEAQ39410853-0688658A-B840-4459-90D5-82BCB431EFDFQ39507595-19753AE1-D700-46F8-9C2B-40D625C38329Q40350619-2991ED72-EE1D-49C9-86FA-BBFA4E67A708Q40653380-A360E683-C16F-4B73-BC8D-49852696239CQ40669638-6AA96879-8BFD-4327-87F7-D3A7E808EDDCQ46654052-02CC9435-8B3D-4E2A-97CF-FFB21F89734AQ48332534-C742E6D3-7658-430B-9BBD-8C11322DDAC4Q49328959-D991CA92-09B3-49C5-91A7-FA8593D90E53Q51099853-2AB0FEAD-ACC9-43E6-89DB-1CDE39ED9F10
P2860
Rational therapeutic intervention in cancer: kinases as drug targets.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Rational therapeutic intervention in cancer: kinases as drug targets.
@ast
Rational therapeutic intervention in cancer: kinases as drug targets.
@en
Rational therapeutic intervention in cancer: kinases as drug targets.
@nl
type
label
Rational therapeutic intervention in cancer: kinases as drug targets.
@ast
Rational therapeutic intervention in cancer: kinases as drug targets.
@en
Rational therapeutic intervention in cancer: kinases as drug targets.
@nl
prefLabel
Rational therapeutic intervention in cancer: kinases as drug targets.
@ast
Rational therapeutic intervention in cancer: kinases as drug targets.
@en
Rational therapeutic intervention in cancer: kinases as drug targets.
@nl
P1476
Rational therapeutic intervention in cancer: kinases as drug targets.
@en
P2093
Charles L Sawyers
P304
P356
10.1016/S0959-437X(01)00273-8
P577
2002-02-01T00:00:00Z